Frank I. Lin
No Rating Available
(Learn About Our Rating System)

Frank I. Lin, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Radiology
50 N Medical Dr
Salt Lake City , UT 84132
801-581-2121
Get Directions

  • Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Nuclear Medicine (Nuc Med)
    American Board of Internal Medicine (Sub: Medical Oncology)

  • Board Certification and Academic Information

    Academic Departments Radiology & Imaging Sciences -Clinical Attending
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Nuclear Medicine (Nuc Med)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Undergraduate Biological Science - Stanford University B.S.
    Graduate Training Medical Informatics - University of Utah M.S.
    Professional Medical Medical College of Wisconsin MD
    Internship/Residency Internal Medicine - Kaiser Permanente - San Francisco Intern/Resident
    Residency Nuclear Medicine - University of California - Davis Resident
    Chief Resident Nuclear Medicine - University of California - Davis Chief Resident
    Research Fellow PET/CT - Stanford University Research Fellow
    Fellowship Medical Oncology - National Cancer Institute Clinical Fellow

    Selected Publications

    Journal Article

    1. Minchom A, Lindén O, Knapen DG, Hassan R, Lin FI, Jalkanen K, Subbiah V, Tafuri A, Ferreira D, Jardine V, Cleton A, Pinkert J, Bladt F, Hennekes H, Smit E (2025). First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. ESMO open, 10(12), 105905. (Read full publication)
    2. Lin FI, Rivero JD, Carrasquillo JA, Jha A, Zou J, Shamis I, Talvacchio S, Turkbey B, Huang EP, Shih J, Klubo-Gwiezdzinska J, Mena E, Lindenberg L, Teng Y, Escorcia FE, Chen C, Herscovitch P, Millo C, Choyke PL, Pacak (2025). Erratum: Phase II Study of (177)Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. Journal of clinical oncology, 43(31), 3427. (Read full publication)
    3. Abel ML, Sharp A, Posadas EM, Karzai F, Lin FI, Choyke PL, Madan R (2025). Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging. Nature reviews. Urology, (Read full publication)
    4. Lin FI, Del Rivero J, Carrasquillo JA, Jha A, Zou J, Shamis I, Talvacchio S, Turkbey B, Huang EP, Shih J, Klubo-Gwiezdzinska J, Mena E, Lindenberg L, Teng Y, Escorcia FE, Chen C, Herscovitch P, Millo C, Choyke PL, Pacak (2025). Phase II Study of (177)Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. Journal of clinical oncology, 43(28), 3102-3112. (Read full publication)
    5. Lee W, Doda SR, Baidoo KE, Nambiar D, Chung JY, Adler S, Edmondson E, Ueda Y, Omiya S, Li X, Makala H, Sheehan-Klenk J, Fayn S, Weiss OJ, Lindberg E, Beck JA, LeBlanc AK, Lin FI, Choyke PL, Swenson R, Schnermann MJ, Escorcia F (2025). Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics. bioRxiv, (Read full publication)
    6. Alkaissi H, Taieb D, Lin FI, Del Rivero J, Wang K, Clifton-Bligh R, Pacak (2025). Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma. The Journal of clinical endocrinology and metabolism, 110(10), 2946-2963. (Read full publication)
    7. Adler SS, Sato N, Baidoo KE, Lin FI, Lee W, Olkowski CP, Escorcia FE, Choyke P (2025). A Quantitative Particle Identification (QPID) spectral autoradiography system. Communications engineering, 4(1), 89. (Read full publication)
    8. Haque F, Chen A, Lay N, Carrasquillo J, Mena E, Lindenberg L, Segal JE, Eclarinal PC, Talvacchio S, Derkyi A, Choyke PL, Pacak K, Kaplan RN, Lin FI, Turkbey B, Harmon S (2025). Development and validation of pan-cancer lesion segmentation AI-model for whole-body 18F-FDG PET/CT in diverse clinical cohorts. Computers in biology and medicine, 190, 110052. (Read full publication)
    9. Fernandes B, Olkowski CP, Ghaemi B, Basuli F, Shi J, Kiesewetter DO, Lang L, Elijah E, Swenson R, Choyke PL, Lin FI, Jacobson (2025). Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics. Journal of controlled release, 379, 478-488. (Read full publication)
    10. Lindenberg L, Hope TA, Lin FI, Rowe SP, Pucar D, Gilbert N, Chicco D, He B, Feuerecker B, Castaldi E, Solnes L (2025). Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer. Journal of nuclear medicine, 66(3), 359-365. (Read full publication)
    11. Haque F, Carrasquillo JA, Turkbey EB, Mena E, Lindenberg L, Eclarinal PC, Nilubol N, Choyke PL, Floudas CS, Lin FI, Turkbey B, Harmon S (2024). An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body (68)Ga- DOTATATE PET/CT. EJNMMI research, 14(1), 103. (Read full publication)
    12. Jha A, Patel M, Ling A, Shah R, Chen CC, Millo C, Nazari MA, Sinaii N, Charles K, Kuo MJM, Prodanov T, Saboury B, Talvacchio S, Derkyi A, Del Rivero J, O'Sullivan Coyne G, Chen AP, Nilubol N, Herscovitch P, Lin FI, Taieb D, Civelek AC, Carrasquillo JA, Pacak (2024). Diagnostic performance of [(68)Ga]DOTATATE PET/CT, [(18)F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma. European radiology, 34(10), 6488-6498. (Read full publication)
    13. Cortez BN, Kuo MJM, Jha A, Patel M, Carrasquillo JA, Prodanov T, Charles KM, Talvacchio S, Derkyi A, Lin FI, Taïeb D, Del Rivero J, Pacak (2024). Case Series: ATRX Variants in Four Patients with Metastatic Pheochromocytoma. Frontiers in endocrinology, 15, 1399847. (Read full publication)
    14. Fernandes B, Roy J, Basuli F, Warner BM, Lindenberg L, Mena E, Adler SS, Griffiths GL, Choyke PL, Lin F (2024). Salivary excretion of systemically injected [(18)F]DCFPyL in prostate cancer patients undergoing PSMA scans. Frontiers in oncology, 14, 1367962. (Read full publication)
    15. Phelps TE, Del Rivero J, Chertow DS, Rosing D, Pacak K, Lin F (2024). Managing Catecholamine Release Syndrome During and Following Lu-177-DOTATATE in High-Risk Pheochromocytoma Patients. JCEM case reports, 2(4), luae049. (Read full publication)
    16. Gubbi S, Al-Jundi M, Auh S, Jha A, Zou J, Shamis I, Meuter L, Knue M, Turkbey B, Lindenberg L, Mena E, Carrasquillo JA, Teng Y, Pacak K, Klubo-Gwiezdzinska J, Del Rivero J, Lin F (2023). Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy. Frontiers in endocrinology, 14, 1275813. (Read full publication)
    17. King AP, Gutsche NT, Raju N, Fayn S, Baidoo KE, Bell MM, Olkowski CS, Swenson RE, Lin FI, Sadowski SM, Adler SS, Thiele NA, Wilson JJ, Choyke PL, Escorcia F (2023). (225)Ac-MACROPATATE: A Novel ¿-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Journal of nuclear medicine, 64(4), 549-554. (Read full publication)
    18. Jha A, Patel M, Carrasquillo JA, Chen CC, Millo C, Maass-Moreno R, Ling A, Lin FI, Lechan RM, Hope TA, Taïeb D, Civelek AC, Pacak (2022). Choice Is Good at Times: The Emergence of [(64)Cu]Cu-DOTATATE-Based Somatostatin Receptor Imaging in the Era of [(68)Ga]Ga-DOTATATE. Journal of nuclear medicine, 63(9), 1300-1301. (Read full publication)
    19. Patel M, Jha A, Ling A, Chen CC, Millo C, Kuo MJM, Nazari MA, Talvacchio S, Charles K, Miettinen M, Del Rivero J, Chen AP, Nilubol N, Lin FI, Civelek AC, Taïeb D, Carrasquillo JA, Pacak (2022). Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma. Cancers, 14(16), (Read full publication)
    20. Mena E, Rowe SP, Shih JH, Lindenberg L, Turkbey B, Fourquet A, Lin FI, Adler S, Eclarinal P, McKinney YL, Citrin DE, Dahut W, Wood BJ, Chang R, Levy E, Merino M, Gorin MA, Pomper MG, Pinto PA, Eary JF, Choyke PL, Pienta K (2022). Predictors of (18)F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. Journal of nuclear medicine, 63(8), 1184-1190. (Read full publication)
    21. Jha A, Patel M, Carrasquillo JA, Ling A, Millo C, Saboury B, Chen CC, Wakim P, Gonzales MK, Meuter L, Knue M, Talvacchio S, Herscovitch P, Rivero JD, Chen AP, Nilubol N, Taïeb D, Lin FI, Civelek AC, Pacak (2022). Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using (68)Ga-DOTATATE, FDG, (18)F-FDOPA, and (18)F-FDA). AJR. American journal of roentgenology, 218(2), 342-350. (Read full publication)
    22. King AP, Lin FI, Escorcia F (2021). Why bother with alpha particles?. European journal of nuclear medicine and molecular imaging, 49(1), 7-17. (Read full publication)
    23. Roy J, White ME, Basuli F, Opina ACL, Wong K, Riba M, Ton AT, Zhang X, Jansson KH, Edmondson E, Butcher D, Lin FI, Choyke PL, Kelly K, Jagoda E (2021). Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [(18)F]DCFPyL PET Imaging. Molecular imaging and biology, 23(5), 745-755. (Read full publication)
    24. Roy J, Warner BM, Basuli F, Zhang X, Zheng C, Goldsmith C, Phelps T, Wong K, Ton AT, Pieschl R, White ME, Swenson R, Chiorini JA, Choyke PL, Lin F (2021). Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study. EJNMMI research, 11(1), 66. (Read full publication)
    25. Roy J, Jagoda EM, Basuli F, Vasalatiy O, Phelps TE, Wong K, Ton AT, Hagemann UB, Cuthbertson AS, Cole PE, Hassan R, Choyke PL, Lin F (2021). In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab. Cancer biotherapy & radiopharmaceuticals, 36(4), 316-325. (Read full publication)
    26. Takebe N, Coyne GO, Kummar S, Collins J, Reid JM, Piekarz R, Moore N, Juwara L, Johnson BC, Bishop R, Lin FI, Mena E, Choyke PL, Lindenberg ML, Rubinstein LV, Bonilla CM, Goetz MP, Ames MM, McGovern RM, Streicher H, Covey JM, Doroshow JH, Chen A (2021). Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. Oncotarget, 12(4), 268-277. (Read full publication)
    27. Gubbi S, Al-Jundi M, Del Rivero J, Jha A, Knue M, Zou J, Turkbey B, Carrasquillo JA, Lin E, Pacak K, Klubo-Gwiezdzinska J, Lin F (2021). Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. Frontiers in endocrinology, 11, 587065. (Read full publication)
    28. Roy J, Warner BM, Basuli F, Zhang X, Wong K, Pranzatelli T, Ton AT, Chiorini JA, Choyke PL, Lin FI, Jagoda E (2020). Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents. Cancer biotherapy & radiopharmaceuticals, 35(4), 284-291. (Read full publication)
    29. Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, Herscovitch P, Adams KT, Taïeb D, Metwalli AR, Linehan WM, Brofferio A, Stratakis CA, Kebebew E, Lodish M, Civelek AC, Pacak (2018). Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. European journal of nuclear medicine and molecular imaging, 45(5), 787-797. (Read full publication)
    30. Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress R (2018). Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. The Lancet. Haematology, 5(1), e44-e52. (Read full publication)
    31. Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, Ling A, Lin FI, Adams KT, Herscovitch P, Feelders RA, Fojo AT, Taieb D, Kebebew E, Pacak (2017). Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. Journal of nuclear medicine, 58(8), 1236-1242. (Read full publication)
    32. Lin FI, Gonzalez EM, Kummar S, Do K, Shih J, Adler S, Kurdziel KA, Ton A, Turkbey B, Jacobs PM, Bhattacharyya S, Chen AP, Collins JM, Doroshow JH, Choyke PL, Lindenberg M (2017). Utility of (18)F-fluoroestradiol ((18)F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. European journal of nuclear medicine and molecular imaging, 44(3), 500-508. (Read full publication)
    33. Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, Buchmann I, Kebebew E, Pacak (2016). PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging, 43(10), 1784-91. (Read full publication)
    34. Mittra ES, Fan-Minogue H, Lin FI, Karamchandani J, Sriram V, Han M, Gambhir S (2013). Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI. Clinical cancer research, 19(20), 5711-21. (Read full publication)
    35. Lin FI, Rao JE, Mittra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, Iagaru (2012). Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. European journal of nuclear medicine and molecular imaging, 39(2), 262-70. (Read full publication)
    36. Lin FI, Foster CC, Shelton D (2011). Radiotracer visualization within a saline breast implant due to inadvertent needle penetration during lymphoscintigraphy. Clinical nuclear medicine, 36(11), 1023-4. (Read full publication)
    37. Thakor AS, Luong R, Paulmurugan R, Lin FI, Kempen P, Zavaleta C, Chu P, Massoud TF, Sinclair R, Gambhir S (2011). The fate and toxicity of Raman-active silica-gold nanoparticles in mice. Science translational medicine, 3(79), 79ra33. (Read full publication)
    38. Lin FI, Foster CC, Hagge RJ, Shelton D (2009). Extensive FDG uptake in accessory muscles of respiration in a patient with shortness of breath. Clinical nuclear medicine, 34(7), 428-30. (Read full publication)
    39. Huang L, Ichimaru E, Pestonjamasp K, Cui X, Nakamura H, Lo GY, Lin FI, Luna EJ, Furthmayr (1998). Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochemical and biophysical research communications, 248(3), 548-53. (Read full publication)
    40. Huang L, Ichimaru E, Pestonjamasp K, Cui X, Nakamura H, Lo GY, Lin FI, Luna EJ, Furthmayr (1998). Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochemical and biophysical research communications, 248(3), 548-53. (Read full publication)
    41. Lin IK, Bray BE, Smith JA, Lange L (2001). The feasibility of remote-controlled assistance as a search tool for patient education. Proceedings. AMIA Symposium, 378-82. (Read full publication)
    42. Monsky WL, Garza AS, Kim I, Loh S, Lin TC, Li CS, Fisher J, Sandhu P, Sidhar V, Chaudhari AJ, Lin F, Deutsch LS, Badawi R (2011). Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. Cardiovascular and interventional radiology, 34(2), 306-18. (Read full publication)
    43. Mittra ES, Fan-Minogue H, Lin FI, Karamchandani J, Sriram V, Han M, Gambhir S (2013). Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI. Clinical cancer research, 19(20), 5711-21. (Read full publication)
    44. Fahey F, Zukotynski K, Jadvar H, Capala J, organizing committee, contributors, and participants of the second NCI'SNMMI Workshop on Targeted Radionuclide Therap (2015). Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy. Journal of nuclear medicine, 56(7), 1119-29. (Read full publication)

    Review

    1. Ghosh I, Benson O, Hernandez-Felix JH, Lin FI, Pacak K, Del Rivero (2025). Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions. Cancers, 17(22), (Read full publication)
    2. Pacak K, Taieb D, Lin FI, Jha (2024). Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient. The Journal of clinical endocrinology and metabolism, 109(9), 2366-2388. (Read full publication)
    3. Taïeb D, Nölting S, Perrier ND, Fassnacht M, Carrasquillo JA, Grossman AB, Clifton-Bligh R, Wanna GB, Schwam ZG, Amar L, Bourdeau I, Casey RT, Crona J, Deal CL, Del Rivero J, Duh QY, Eisenhofer G, Fojo T, Ghayee HK, Gimenez-Roqueplo AP, Gill AJ, Hicks R, Imperiale A, Jha A, Kerstens MN, de Krijger RR, Lacroix A, Lazurova I, Lin FI, Lussey-Lepoutre C, Maher ER, Mete O, Naruse M, Nilubol N, Robledo M, Sebag F, Shah NS, Tanabe A, Thompson GB, Timmers HJLM, Widimsky J, Young WJ Jr, Meuter L, Lenders JWM, Pacak (2024). Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nature reviews. Endocrinology, 20(3), 168-184. (Read full publication)
    4. Carrasquillo JA, Chen CC, Jha A, Pacak K, Pryma DA, Lin F (2021). Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Journal of nuclear medicine, 62(9), 1192-1199. (Read full publication)
    5. Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, Pacak (2021). Imaging of Pheochromocytoma and Paraganglioma. Journal of nuclear medicine, 62(8), 1033-1042. (Read full publication)
    6. Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum JC, Coleman NC, Dewaraja YK, Frey E, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos CA, Larson S, Lin FI, Madsen M, Mirzadeh S, Morse D, Pryma D, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico P, Zukotynski (2021). Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Journal of nuclear medicine, 62(8), 1133-1139. (Read full publication)
    7. Jha A, Taïeb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru AH, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak (2021). High-Specific-Activity-(131)I-MIBG versus (177)Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical cancer research, 27(11), 2989-2995. (Read full publication)
    8. Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule H (2020). Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. The Prostate, 80(15), 1273-1296. (Read full publication)
    9. Huang EP, Lin FI, Shankar L (2017). Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design. Academic radiology, 24(8), 1036-1049. (Read full publication)
    10. Lin FI, Huang EP, Shankar L (2017). Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment. Academic radiology, 24(8), 1027-1035. (Read full publication)
    11. Chen KY, Cypess AM, Laughlin MR, Haft CR, Hu HH, Bredella MA, Enerbäck S, Kinahan PE, Lichtenbelt Wv, Lin FI, Sunderland JJ, Virtanen KA, Wahl R (2016). Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans. Cell metabolism, 24(2), 210-22. (Read full publication)
    12. Lin FI, Iagaru (2010). Current concepts and future directions in radioimmunotherapy. Current drug discovery technologies, 7(4), 253-62. (Read full publication)

    Letter

    1. Malaza G, Brofferio A, Lin F, Pacak (2019). Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. The New England journal of medicine, 380(13), 1284-1286. (Read full publication)

    Other

    1. Cortez BN, Kuo MJM, Jha A, Patel M, Carrasquillo JA, Prodanov T, Charles KM, Talvacchio S, Derkyi A, Lin FI, Taïeb D, Del Rivero J, Pacak (2025). Correction: Case series: ATRX variants in four patients with metastatic pheochromocytoma. Frontiers in endocrinology, 16, 1736207. (Read full publication)